Anti-thrombin III (ATIII) vs Placebo in Children (<7mo) Undergoing Open Congenital Cardiac Surgery
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test whether the administration of ATIII during the
intra-operative period results in improved anticoagulation for cardiopulmonary bypass (CPB)
and an attenuation of the activation of the coagulation cascade, as represented by a decrease
in fibrin degradation products. The investigators believe this benefit would extend into the
post-operative period resulting in a decreased incidence of thrombosis generation, as
represented by a decrease in fibrin degradation products in the ICU period.